Development and in vivo evaluation of fused benzazole analogs of anti-melanoma agent HA15

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Uong A, Zon LI. Melanocytes in development and cancer. J. Cell. Physiol. 222, 38–41 (2010).
  Medline CASGoogle Scholar
• 2. Bonaventure J, Domingues MJ, Larue L. Cellular and molecular mechanisms controlling the migration of melanocytes and melanoma cells. Pigm. Cell. Melanoma. Res. 26(3), 316–325 (2013).
  Medline CASGoogle Scholar
• 3. Bandarchi B, Jabbari CA, Vedadi A, Navab R. Molecular biology of normal melanocytes and melanoma cells. J. Clin. Pathol. 66, 644–648 (2013).
  Medline CASGoogle Scholar
• 4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 5. Mandalà M, Voit C. Targeting BRAF in melanoma: biological and clinical challenges. Crit. Rev. Oncol. Hem. 87(3), 239–255 (2013).
  MedlineGoogle Scholar
• 6. Fort M, Guet S, Husheng S, Calitchi E, Belkacemi Y. Role of radiation therapy in melanomas: systematic review and best practice in 2016. Crit. Rev. Oncol. Hem. 99, 362–375 (2016).
  MedlineGoogle Scholar
• 7. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther. Adv. Med. Oncol. 7(2), 122–136 (2015). •• Interesting review article surveying compounds approved and under evaluation for melanoma.
  Medline CASGoogle Scholar
• 8. Domingues B, Lopes J, Soares P, Populo H. Melanoma treatment in review. ImmunoTargets Ther. 7, 35–49 (2018).
  Medline CASGoogle Scholar
• 9. Liu Y, Hao Y, Li Y, Zheng Y, Dai J, Zhong F. Salinomycin induces autophagic cell death in salinomycin – sensitive melanoma cells through inhibition of autophagic flux. Sci. Rep. 10, 18515 (2020).
  Medline CASGoogle Scholar
• 10. Ronco C, Millet A, Plaisant M et al. Structure activity relationship and optimization of N-(3-(2-aminothiazol-4-yl)aryl)benzenesulfonamides as anti-cancer compounds against sensitive and resistant cells. Bioorg. Med. Chem. Lett. 27(10), 2192–2196 (2017). •• Presents the first attempt to the optimization of HA15 and the discovery of 2 (PB615).
  Medline CASGoogle Scholar
• 11. Cerezo M, Lehraiki A, Millet A et al. Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance. Cancer Cell 29(6), 805–819 (2016).
  Medline CASGoogle Scholar
• 12. Ronco C, Rocchi S, Benhida R. Expression level of GRP78/BiP as a predictor of favorable or unfavorable outcomes in cancer patients. Mediastinum 2, 26 (2018).
  Google Scholar
• 13. Ruggiero C, Doghman-Bouguerra M, Ronco C, Benhida R, Rocchi S, Lalli E. The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. Mol. Cell. Endocrinol. 474, 57–64 (2018). • Evidences the synergistic effect of HA15 and mitotane on adrenocortical carcinoma cells.
  Medline CASGoogle Scholar
• 14. Xu D, Yang H, Yang Z et al. Endoplasmic reticulum stress signaling as a therapeutic target in malignant pleural mesothelioma. Cancers 11(10), 1502 (2019).
  CASGoogle Scholar
• 15. Moriya C, Taniguchi H, Nagatoishi S, Igarashi H, Tsumoto K, Imai K. PRDM14 directly interacts with heat shock proteins HSP90α and glucose-regulated protein 78. Cancer Sci. 109(2), 373–383 (2018).
  Medline CASGoogle Scholar
• 16. Cheng CC, Yang BL, Chen WC et al. STAT3 mediated miR-30a-5p inhibition enhances proliferation and inhibits apoptosis in colorectal cancer cells. Int. J. Mol. Sci. 21(19), 7315 (2020).
  CASGoogle Scholar
• 17. Millet A, Plaisant M, Ronco C et al. Discovery and optimization of N-(4-(3-aminophenyl)thiazol-2-yl)acetamide as a novel scaffold active against sensitive and resistant cancer cells. J. Med. Chem. 59(18), 8276–8292 (2016). •• Discloses the discovery, the mechanism of action and the biological target of HA15.
  Medline CASGoogle Scholar
• 18. Mendel LR, Porter CC, Kuehl FA Jr. Inhibition of adrenal phenethanolamine. J. Med. Chem. 13(6), 1043–1047 (1970).
  MedlineGoogle Scholar
• 19. Schütte J, Kilgenstein F, Fischer M, Koert U et al. Unsymmetrical vic‐tricarbonyl compounds for the total syntheses of cladoniamide G and cladoniamide F. Eur. J. Org. Chem. 5302–5311 (2014).
  Google Scholar
• 20. Tomic T, Botton T, Cerezo M et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2(9), e199 (2011).
  Medline CASGoogle Scholar
• 21. Corazao-Rozas P, Guerreschi P, Jendoubi M et al. Mitochondrial oxidative stress is the Achilles heel of melanoma cells resistant to BRAF-mutant inhibitor. Oncotarget 4(11), 1986–1998 (2013).
  MedlineGoogle Scholar
• 22. Miot-Noirault E, Legault J, Cachin F et al. Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma. Invest. New Drugs 22, 369–378 (2004).
  Medline CASGoogle Scholar
• 23. Grytsai O, Druzhenko T, Demange L, Ronco C, Benhida R. Cyanoguanidine as a versatile, eco-friendly and inexpensive reagent for the synthesis of 2-aminobenzoxazoles and 2-guanidinobenzoxazoles. Tetrahedron Lett. 59(17), 1642–1645 (2018).
  CASGoogle Scholar